Morquio Type A vs. Type B: What is the Difference?
At a Glance
Morquio syndrome Type A and Type B both cause skeletal changes but result from different missing enzymes. Type A is usually more severe and has an FDA-approved enzyme replacement therapy. Type B is generally milder with no approved targeted treatment, focusing instead on symptom management.
In this answer
3 sections
Morquio syndrome, also known as Mucopolysaccharidosis type IV (MPS IV), is divided into two types: Type A and Type B. Both types are inherited in an autosomal recessive pattern, meaning a child must inherit the mutated gene from both parents [1]. While both types cause similar bone and skeletal changes because they affect how the body breaks down complex sugars—specifically keratan sulfate (and chondroitin-6-sulfate in Type A)—they are caused by different deficient enzymes and have different treatment options [1]. In general, Type A is more common and often more severe, whereas Type B is typically milder and does not currently have an approved enzyme replacement therapy [1]. Doctors distinguish between the two types using blood tests to measure enzyme activity or genetic testing [2].
The Biology: Different Deficient Enzymes
Every person with Morquio syndrome does not have enough of a specific working enzyme needed to break down sugars in the body’s cells. The exact enzyme that is deficient determines the type of Morquio syndrome:
- Morquio Type A: Caused by mutations in the GALNS gene, leading to a deficiency of an enzyme called N-acetylgalactosamine-6-sulfatase [1].
- Morquio Type B: Caused by mutations in the GLB1 gene, leading to a deficiency of an enzyme called beta-galactosidase [1].
Severity and Physical Differences
Both types present with dysostosis multiplex, the medical term for the widespread bone and skeletal changes seen in MPS conditions [1]. This includes joint laxity (loose joints), spinal curvature (kyphoscoliosis), and issues with the bones in the neck [1].
However, how the condition develops differs between the two:
- Growth and Stature: While both types cause growth impairment, the skeletal changes in Type B are generally milder than in Type A [1]. Adults with Type B are typically taller than adults with Type A, although they still usually have a final height well below average [1].
- Neurological Symptoms: Morquio Type A typically does not directly affect a person’s cognitive function or brain health. “Pure” Morquio Type B also only involves skeletal features [1]. However, Morquio Type B is genetically linked to another condition called GM1-gangliosidosis [1]. Some rare individuals have “Morquio B plus,” a variant that includes neurological symptoms like delayed cognitive development, balance issues, or involuntary muscle contractions [1]. It is important to know that classic Morquio B does not impact intelligence.
Treatment Options and Daily Life
One of the most crucial differences for patients and families to understand is the availability of targeted treatments, though both require extensive day-to-day management.
- Treating Type A: There is an FDA-approved Enzyme Replacement Therapy (ERT) for Morquio Type A, known as elosulfase alfa (Vimizim). This treatment works by providing the body with the GALNS enzyme it is missing, which has been shown to stabilize or improve endurance and lung function, protecting certain organs [3][4]. However, ERT does not cure the condition or stop the progression of bone and skeletal changes, because it cannot easily reach bone tissue.
- Treating Type B: Currently, there is no approved ERT for Morquio Type B [1]. Because Type B is caused by a different deficient enzyme, the ERT used for Type A will not work for Type B patients. Researchers are actively exploring future treatments like gene therapy for both types [5].
Living with Morquio Syndrome
Regardless of whether a patient has Type A or Type B, the condition involves significant daily realities. Active management by a care team often means addressing chronic pain and preparing for major orthopedic surgeries, such as spinal fusions or leg procedures, to maintain mobility and protect the spinal cord [1][6]. Day-to-day quality of life is heavily supported by physical therapy and mobility aids—like wheelchairs, scooters, or walkers—to help conserve energy and maintain independence.
A coordinated care team of specialists (including orthopedists, cardiologists, and pulmonologists) is essential to manage complications, such as spinal cord compression, vision issues from corneal clouding, and heart valve problems [1][6].
Common questions in this guide
What causes Morquio syndrome Type A versus Type B?
Is Morquio syndrome Type A more severe than Type B?
Is there a treatment for Morquio syndrome Type B?
Does enzyme replacement therapy cure Morquio Type A?
Does Morquio syndrome affect a person's intelligence?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
About testing
Would blood tests for enzyme activity or genetic testing help show which type applies to me?
Treatment options
Is enzyme replacement therapy available for each type, and how do they differ?
Daily life
How could physical therapy and mobility aids support my daily life?
Related questions
Show more
Get notified when new evidence is published on Mucopolysaccharidosis type 4.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (6)
- 1
Morquio B Disease. Disease Characteristics and Treatment Options of a Distinct GLB1-Related Dysostosis Multiplex.
Yuskiv N, Higaki K, Stockler-Ipsiroglu S
International journal of molecular sciences 2020; (21(23)) doi:10.3390/ijms21239121.
PMID: 33266180 - 2
Mucopolysaccharidosis type IVA (Morquio A) in twins masquerading as distal renal tubular acidosis.
Jethwani P, Patra S, Pande M, Kedar K
BMJ case reports 2025; (18(5)) doi:10.1136/bcr-2024-264555.
PMID: 40409777 - 3
Long-term outcomes of enzyme replacement therapy from a large cohort of Korean patients with mucopolysaccharidosis IVA (Morquio A syndrome).
Sung J, Kim I, Im M, et al.
Molecular genetics and metabolism reports 2025; (42()):101189 doi:10.1016/j.ymgmr.2025.101189.
PMID: 39897469 - 4
Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management.
Sawamoto K, Álvarez González JV, Piechnik M, et al.
International journal of molecular sciences 2020; (21(4)) doi:10.3390/ijms21041517.
PMID: 32102177 - 5
Assessment of different promoters in lentiviral vectors for expression of the N-acetyl-galactosamine-6-sulfate sulfatase gene.
Celik B, Leal AF, Khan S, Tomatsu S
Journal of human genetics 2025; (70(9)):463-473 doi:10.1038/s10038-025-01353-x.
PMID: 40494905 - 6
Implementation of newborn screening for mucopolysaccharidosis type IVA and long-term monitoring in Taiwan.
Lin HY, Lee CL, Chang YH, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2024; (26(12)):101286 doi:10.1016/j.gim.2024.101286.
PMID: 39375993
This page explains the differences between Morquio syndrome types for educational purposes. Always consult your medical genetics team or healthcare provider for specific diagnostic and treatment advice.